AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

Calendar

09-30 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
31/08/26	€0.7030	-2.77%	284,132
28/08/26	€0.7230	0.00%	250,769
27/08/26	€0.7230	+1.40%	356,181
26/08/26	€0.7130	-3.52%	507,804
25/08/26	€0.7390	+9.97%	1,001,446

Real-time Euronext Paris

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Paris 18:55:00 31/08/2026 +03			After hours 23:00:00
0.7030 ^EUR	-2.77%		0.7020	-0.14%

08-17	AB Science completes settlement and delivery of its private placement
08-10	AB Science Wraps Up EUR14 Million Private Placements	MT

Market Cap	56.25M 65.33M 52.82M 48.21M 90.57M 6.22B 91.22M 626M 244M 3.15B 245M 240M 10.44B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	56.25M 65.33M 52.82M 48.21M 90.57M 6.22B 91.22M 626M 244M 3.15B 245M 240M 10.44B	EV / Sales 2026 *	46.9x	EV / Sales 2027 *	43.3x
Free-Float	69.03%	Yield 2026 *	-	Yield 2027 *	-

08-17	AB Science completes settlement and delivery of its private placement
08-10	AB Science Wraps Up EUR14 Million Private Placements	MT
08-10	AB Science raises €14.2m
07-13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
07-10	AB Science streamlines its portfolio and refocuses on two molecules
07-10	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
07-08	Stéphane Ledermann takes the helm at AB Science as CEO
07-07	AB Science S.A. Announces Board Changes	CI
07-07	AB Science S.A. Announces CEO Changes	CI
07-03	AB Science S.A. announced that it has received $2.01616 million in funding	CI
07-01	AB Science, successful private placement
07-01	AB Science S.A. announced that it has received ?2.294 million in funding	CI
06-29	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI

08-17	AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026	GL
08-10	AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million	GL
08-04	AB Science : Webconference presentation on masitinib + isoquercetin in COVID-19	PU
07-10	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
07-08	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU

AB Science Stock

Stocks

AB

FR0010557264

Pharmaceuticals

Valuation : AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript : AB Science

Press Releases : AB Science

News in other languages : AB Science

Quotes and Performance

Price Extremes

Managers and Directors : AB Science

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

08-24	AB Science : Franchissement de seuils et déclaration d'intention
08-17	Bourse : Stellantis s'agite, ArgenX communique et PayPal fait monter les enchères
08-17	AB Science procède au règlement-livraison de son placement privé
08-17	AB Science : annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026
08-17	AB Science annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026

1 day	-2.77%
1 week	+1.44%
Current month	+29.94%
1 month	+32.39%
3 months	-27.07%
6 months	-45.92%
Current year	-54.23%

1 week	0.67	0.78
1 month	0.54	1
Current year	0.5	1.61
1 year	0.5	1.68
3 years	0.5	4.46
5 years	0.5	14.53
10 years	0.5	21.75

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	64	27/06/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
5/20/26 A	Alain Moussy	Sell	Chief Executive Officer	-573	0.0009%
2/9/21 A	Jean-Pierre Kinet	Sell	Founder	14,525	0.0315%
2/2/21 A	Jean-Pierre Kinet	Sell	Founder	76,104	0.1652%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-2.77%	+1.44%	-41.22%	-75.92%	67.14M
MERCK & CO., INC.	-0.40%	-1.92%	+72.86%	+35.58%	366B
MERCK KGAA	-0.89%	+0.43%	+27.87%	-16.27%	70.76B
HALOZYME THERAPEUTICS, INC.	+1.08%	-1.98%	+45.20%	+150.21%	11.96B
KYOWA KIRIN CO., LTD.	-1.33%	+2.00%	+3.26%	-1.02%	8.72B
SK BIOPHARMACEUTICALS CO., LTD.	-0.80%	+4.30%	-11.46%	+0.92%	5B
YUHAN CORPORATION	-1.41%	+1.70%	-26.26%	+21.05%	4.59B
BETTA PHARMACEUTICALS CO., LTD.	-0.14%	-1.37%	-28.57%	+2.92%	3.16B
SUPERNUS PHARMACEUTICALS, INC.	+1.10%	-2.00%	-0.74%	+38.85%	2.54B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-2.27%	-3.75%	-17.97%	-14.26%	2.08B
Average	-0.69%	+0.26%	+2.30%	+14.21%	47.49B
Weighted average by Cap.	+0.34%	-1.85%	+60.85%	+29.13%

	2026 *	2027 *
Net sales	1.2M 1.39M 1.13M 1.03M 1.93M 133M 1.95M 13.35M 5.19M 67.25M 5.23M 5.12M 223M	1.3M 1.51M 1.22M 1.11M 2.09M 144M 2.11M 14.46M 5.63M 72.85M 5.67M 5.55M 241M
Net income	-	-
Net Debt	-	-